Acutus Medical Reports Third Quarter 2021 Financial Results Carlsbad, Calif.

The following excerpt is from the company's SEC filing.
 – November 11, 2021 – Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today reported results for the third quarter of 2021.
Recent Highlights:
Significant progress was achieved in our three core technology categories:
Left heart access: Revenues advanced three-fold in the third quarter versus prior year; initiated launch in our Europe and UK direct businesses
Mapping and therapy guidance: Initiated limited release of groundbreaking software upgrade AcQMap 8 with automated region of interest locator
Therapy: Initiated Pulsed Filed Ablation (PFA) CE Mark study with first cases in Prague, Czech Republic
Reported revenue of $4.6 million in the third quarter of 2021, compared to $3.2 million in the same quarter last year, led by increased procedure volumes and adoption of AcQMap globally
Ended the third quarter with an installed base of 71 AcQMap mapping consoles. Within the quarter, several consoles were repositioned to different hospitals to drive higher utilization rates and procedure volumes
“During the quarter, we further strengthened our portfolio and market position in our left heart access, mapping and therapy guidance, and therapy categories,” said Vince Burgess, President & CEO of Acutus. “Our innovative left heart access product line has been very well received by electrophysiologists and structural heart specialists, and we continue to expand our product offering in this area. In mapping and therapy guidance, our software team delivered a first-in-the-industry mapping software upgrade with automated region of interest locators that helps physicians better tailor their therapy for each patient while minimizing destruction of healthy tissue. In therapy, we continued to install therapeutic ablation systems in Europe and the U.S. in support of our EU market launch and clinical trial activities, and now have nearly 40 of these systems in place. We also made significant strides with our integrated PFA therapy system allowing us to initiate enrollment in our Pulsed Field Ablation CE mark trial this week in the Czech Republic.”
Mr. Burgess continued “While we have made meaningful progress advancing our pipeline and technology leadership strategy, we have seen ongoing challenges in the external environment as well as gaps in our own commercial execution. With end-markets stabilizing in the fourth quarter, we are intensifying our commercial focus to drive higher account penetration and expanded product adoption across all three of our technology categories.”
Third Quarter 2021 Financial Results
Revenue was $4.6 million for the third quarter of 2021, compared to $3.2 million in the third quarter last year. The improvement over the same quarter last year was driven by increased direct sales of Acutus disposables and higher procedure volumes, as well as increased distributor sales through the Company’s partner, Biotronik. Gross margin on a GAAP basis was negative 86% for the third quarter of 2021, compared with negative 62% in the same quarter last year. The change was driven by unfavorable product and geographic mix. We continue to make significant investments in our manufacturing infrastructure to support rapid adoption of our broad product portfolio and to position us to scale in-house production as our business grows. As production volumes increase over time and we recognize the benefits of cost optimization initiatives, we expect our gross margin to improve.
Operating expenses on a GAAP basis were $23.2 million for the third quarter of 2021, compared with $24.3 million in the same quarter last year. The decrease was primarily driven by a change in fair value of the contingent consideration related to the acquisition of Rhythm Xience, partially offset by increases driven by the expansion of Acutus’ research and development team.
Net loss on a GAAP basis was $28.5 million for the third quarter of 2021 and net loss per share was $0.94 on a weighted average basic and diluted outstanding share count of 30.5 million, compared to $31.2 million and a net loss per share of $1.95 on a weighted average basic and diluted outstanding share count of 16.1 million in the same period of the prior year. Excluding amortization of acquired intangibles, non-cash stock-based compensation expense, remeasurement of the warrant liability, and changes in the fair value of contingent consideration, the Company’s non-GAAP net loss for the third quarter of 2021 was $26.7 million, or $0.87 per share, compared to $21.0 million, or $0.90 per share, after giving effect to the pro forma conversion of convertible preferred stock for the third quarter of 2020.
Press Release
Cash, cash equivalents, marketable securities and restricted cash were $134.7 million as of September 30, 2021. Our secondary equity offering, which was completed in July, resulted in additional net cash proceeds of $82.7 million.
Outlook and COVID-19
Headwinds associated with COVID-19 have moderated in recent weeks; however, there remains meaningful uncertainty - and limited precedent - to predict the duration or sustainability of a recovery. Management continues to view the current situation with COVID-19 as being fluid, and the potential impact on the Company’s business from hospital and government actions in response to potential resurgences in COVID-19 cases, COVID-19-related hospital admissions, restrictions on lab access and new technology assessments and hospital staffing shortages are all factors that could influence performance for the foreseeable future. Taking into consideration year-to-date results, external factors, and business performance, management now projects full year sales to range between $17.0 and $17.5 million.
Non-GAAP Financial Measures
This press release includes references to non-GAAP net loss and non-GAAP net loss per share, which are non-GAAP financial measures, to provide information that may assist investors in understanding the Company’s financial results and assessing its prospects for future performance. The Company believes these non-GAAP financial measures are important indicators of its operating performance because they exclude items that are primarily non-cash accounting line items unrelated to, and may not be indicative of, the Company’s core operating results. These non-GAAP financial measures, as Acutus calculates them, may not necessarily be comparable to similarly titled measures of other companies and may not be appropriate measures for comparing the performance of other companies relative to the Company. These non-GAAP financial results are not intended to represent and should not be considered to be more meaningful measures than, or alternatives to, measures of operating performance as determined in accordance with GAAP. Non-GAAP net loss is defined as net loss before income taxes, adjusted for stock-based compensation, amortization of acquisition-related intangibles, acquisition related costs, discontinued operations, asset impairments, non-operating items, restructuring charges, stock repurchases and other adjustments. To the extent such non-GAAP financial measures are used in the future, the Company expects to calculate them using a consistent method from period to period. A reconciliation of the most directly comparable GAAP financial measure to the non-GAAP financial measure has been provided under the heading “Reconciliation of GAAP Results to Non-GAAP Results” in the financial statement tables attached to this press release.
Webcast and Conference Call Information
Acutus will host a conference call to discuss the third quarter 2021 financial results after market close on Thursday, November 11, 2021 at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. The conference call can be accessed live over the phone (833) 570-1131 for U.S. callers or (914) 987-7078 for international callers, using conference ID: 7373938 . The live webinar can be accessed at
https://ir.acutusmedical.com
About Acutus Medical, Inc.
Acutus is an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated. Acutus is committed to advancing the field of electrophysiology with a unique array of products and technologies which will enable more physicians to treat more patients more efficiently and effectively. Through internal product development, acquisitions and global partnerships, Acutus has established a global sales presence delivering a broad portfolio of highly differentiated electrophysiology products that provide its customers with a complete solution for catheter-based treatment of cardiac arrhythmias. Founded in 2011, Acutus is based in Carlsbad, California.
Caution Regarding Forward-Looking Statements
This press release includes statements that may constitute “forward-looking” statements, usually containing the words “believe,” “estimate,” “project,” “expect” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company’s ability to continue to manage expenses and cash burn rate at sustainable levels, continued acceptance of its products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase the Company’s systems and the timing of such purchases, competitive factors, changes resulting from healthcare policy in the United States and globally, including changes in government reimbursement of procedures, dependence upon third-party vendors and distributors, timing of regulatory approvals, the impact of the coronavirus (COVID-19) pandemic and Acutus’ response to it, and other risks discussed in the Company’s periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, Acutus undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
Investor Contact:
Media Contact:
Caroline Corner
Holly Windler
Westwicke ICR
M: 619-929-1275
D: 415-202-5678
media@acutusmedical.com
caroline.corner@westwicke.com
Consolidated Balance Sheets
(in thousands, except per share amounts)
September 30,
December 31,
(unaudited)
ASSETS
Current assets:
Cash and cash equivalents
58,492 
25,234 
Marketable securities, short-term
71,962 
105,839 
Restricted cash
Accounts receivable
4,190 
2,160 
Inventory
14,962 
12,958 
Prepaid expenses and other current assets
6,045 
5,047 
Total current assets
155,801 
151,388 
Marketable securities, long-term
4,061 
8,726 
Property and equipment, net
14,595 
12,356 
Right-of-use assets, net
4,682 
1,669 
Intangible assets, net
5,173 
5,653 
Goodwill
12,026 
Other assets
1,086 
Total assets
197,424
192,535
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable
6,417 
8,266 
Accrued liabilities
9,398 
7,308 
Contingent consideration, short-term
1,900 
5,400 
Operating lease liabilities, short-term
Total current liabilities
18,181 
21,907 
Operating lease liabilities, long-term
4,695 
1,134 
Long-term debt
40,043 
39,011 
Contingent consideration, long-term
3,900 
Other long-term liabilities
Total liabilities
63,737 
65,952 
Stockholders' equity
Preferred stock, $0.001 par value
Common stock, $0.001 par value
Additional paid-in capital
581,133 
487,290 
Accumulated deficit
(447,434)
(361,015)
Accumulated other comprehensive income (loss)
Total stockholders' equity
133,687 
126,583 
Total liabilities and stockholders' equity
Consolidated Statements of Operations and Comprehensive Loss
Three Months Ended
Nine Months Ended
(in thousands, except share and per share amounts)
4,601 
3,173 
12,901 
5,890 
Costs and operating expenses:
Cost of products sold
8,539 
5,141 
22,986 
10,998 
Research and development
9,299 
8,343 
27,843 
24,492 
Selling, general and administrative
15,805 
15,833 
47,658 
35,193 
Change in fair value of contingent consideration
(1,953)
(3,364)
(1,466)
Total costs and operating expenses
31,690 
29,435 
95,123 
69,217 
Loss from operations
(27,089)
(26,262)
(82,222)
(63,327)
Other income (expense):
Change in fair value of warrant liability
(3,683)
(5,555)
Interest income
Interest expense
(1,441)
(1,366)
(4,285)
(4,090)
Total other expense, net
(1,422)
(5,026)
(4,197)
(9,252)
Loss before income taxes
(28,511)
(31,288)
(86,419)
(72,579)
Income tax benefit
Other comprehensive income (loss)
Unrealized loss on marketable securities
Foreign currency translation adjustment
Comprehensive loss
(28,707)
(31,219)
(86,739)
(72,482)
Net loss per common share, basic and diluted
(0.94)
(1.95)
(2.99)
(12.36)
Weighted average shares outstanding, basic and diluted
30,460,466 
16,080,467 
28,890,382 
5,870,861 
Consolidated Statements of Cash Flows
(in thousands)
Cash flows from operating activities
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense
4,227 
1,754 
Amortization of intangible assets
Stock-based compensation expense
10,263 
9,272 
Amortization of premiums/(accretion of discounts) on marketable securities, net
1,011 
Amortization of debt issuance costs
1,032 
Amortization of right-of-use assets
5,555 
Changes in operating assets and liabilities:
(2,030)
(1,630)
(2,004)
(1,865)
(2,729)
(1,813)
1,862 
1,423 
Net cash used in operating activities
(77,101)
(61,038)
Cash flows from investing activities
Purchases of available-for-sale marketable securities
(70,020)
(108,528)
Sales of available-for-sale marketable securities
8,590 
17,095 
Maturities of available-for-sale marketable securities
98,507 
45,000 
Purchases of property and equipment
(6,587)
(7,822)
Net cash provided by (used in) investing activities
30,490 
(54,255)
Cash flows from financing activities
Payment of deferred offering costs
Payment of contingent consideration
(3,152)
(2,636)
Proceeds from the issuance of common stock, net of issuance costs
82,664 
166,286 
Proceeds from stock options exercises
Proceeds from Employee Stock Purchase Plan
Net cash provided by financing activities
80,083 
164,000 
Effect of exchange rate changes on cash, cash equivalents and restricted cash
Net change in cash, cash equivalents and restricted cash
33,258 
48,850 
Cash, cash equivalents and restricted cash, at the beginning of the period
25,384 
9,602 
Cash, cash equivalents and restricted cash, at the end of the period
58,642
58,452
Reconciliation of GAAP Results to Non-GAAP Results
(Unaudited)
Three Months Ended September 30, 2021
Other expenses, net
Basic and diluted EPS
Amortization of acquired intangibles
(2,767)
3,577 
(0.06)
Adjusted
13,033
(25,305)
(26,727)
(0.87)
Three Months Ended September 30, 2020
Adjustment for assumed conversion of convertible preferred stock
(6,008)
6,374 
3,683 
(19,660)
(1,343)
(21,003)
(0.90)
Denominator
Weighted average shares of common stock outstanding used in GAAP per share calculations
Adjustments to reflect the assumed conversion of convertible preferred stock
7,205,624 
Shares used in non-GAAP per share calculations
23,286,091 
Assumes the conversion of outstanding shares of convertible preferred stock into shares of common stock as if such conversion had occurred at the beginning of the period or their issuance dates, if later.
Key Business Metrics
Installed Base
The total installed base as of September 30, 2021 and 2020 is set forth in the table below:
As of September 30,
Acutus Direct
Outside U.S.
Total Acutus Direct
Total installed base
The net increase in installed base for the three and nine months ended September 30, 2021 and 2020, exclusive of transfers between Acutus and Biotronik, is set forth in the table below:
Nine Months Ended September 30,
Net systems to Biotronik
Total net system placements
The following table sets forth the Company’s revenue for disposables, systems and service/other for the three and nine months ended September 30, 2021 and 2020 (in thousands):
Three Month Ended September 30,
Nine Month Ended September 30,
Disposables
2,437 
1,680 
7,036 
3,599 
Systems
1,626 
1,485 
Service/Other
Total Acutus direct revenue
2,674 
8,853 
5,131 
Distribution agreements
1,700 
4,048 
Total revenue
The following table provides revenue by geographic location for the three and nine months ended September 30, 2021 and 2020 (in thousands):
2,164 
1,790 
5,976 
3,103 
Outside the United States
2,877 
2,028 
Distribution Agreements
1,675 
3,767 
Total revenue through distribution agreements

The above information was disclosed in a filing to the SEC. To see the filing, click here.

To receive a free e-mail notification whenever Acutus Medical, Inc. makes a similar move, sign up!

Other recent filings from the company include the following:

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or - June 24, 2022
Acutus Medical, Inc. director just disposed of 60,000 shares - June 3, 2022
Acutus Medical, Inc.'s Chief Financial Officer just picked up 100,000 shares - June 2, 2022

Auto Refresh

Feedback